PGEN Long Call Strategy

PGEN (Precigen, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC.

PGEN (Precigen, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.63B, a trailing P/E of 66.64, a beta of 0.98 versus the broader market, a 52-week range of 3.04-8.98, average daily share volume of 5.6M, a public-listing history dating back to 2013, approximately 160 full-time employees. These structural characteristics shape how PGEN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.98 places PGEN roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. The trailing P/E of 66.64 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.

What is a long call on PGEN?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

PGEN snapshot

As of November 13, 2026, spot at $4.54, ATM IV 90.50%, IV rank 39.58%, expected move 25.95%. The long call on PGEN below is built from the November 13, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.

Why this long call structure on PGEN specifically: PGEN IV at 90.50% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 25.95% (roughly $1.18 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PGEN expiries trade a higher absolute premium for lower per-day decay. Position sizing on PGEN should anchor to the underlying notional of $4.54 per share and to the trader's directional view on PGEN stock.

PGEN long call setup

The PGEN long call below is built from the November 13, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PGEN at $4.54 on that close, the first option leg uses a $4.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PGEN chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PGEN shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$4.50$0.70

PGEN long call risk and reward

Net Premium / Debit
-$70.00
Max Profit (per contract)
Unbounded
Max Loss (per contract)
-$70.00
Breakeven(s)
$5.20
Risk / Reward Ratio
Unbounded

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

PGEN long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on PGEN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

PGEN long call profit and loss curve at expiration with breakevens and current spot markedPGEN long call payoff at expiration$0$100$200$300$2$4$6$8Underlying Price ($)P&L at Expiration ($)BE $5.20Spot $4.54
P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.
Underlying Price% From SpotP&L at Expiration
$0.01-99.8%-$70.00
$1.01-77.7%-$70.00
$2.02-55.6%-$70.00
$3.02-33.5%-$70.00
$4.02-11.4%-$70.00
$5.02+10.7%-$17.64
$6.03+32.7%+$82.63
$7.03+54.8%+$182.90
$8.03+76.9%+$283.17
$9.03+99.0%+$383.44

When traders use long call on PGEN

Long calls on PGEN express a bullish thesis with defined risk; traders use them ahead of PGEN catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

PGEN thesis for this long call

The market-implied 1-standard-deviation range for PGEN extends from approximately $3.36 on the downside to $5.72 on the upside. A PGEN long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current PGEN IV rank near 39.58% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on PGEN should anchor more to the directional view and the expected-move geometry. As a Healthcare name, PGEN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PGEN-specific events.

PGEN long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PGEN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PGEN alongside the broader basket even when PGEN-specific fundamentals are unchanged. Long-premium structures like a long call on PGEN are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current PGEN chain quotes before placing a trade.

Frequently asked questions

What is a long call on PGEN?
A long call on PGEN is the long call strategy applied to PGEN (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With PGEN stock at $4.54 on the November 13, 2026 close, the strikes shown on this page are snapped to the nearest listed PGEN chain strike and the premiums come straight from that session's bid/ask midpoint.
How are PGEN long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the PGEN long call priced from the November 13, 2026 end-of-day chain at a 30-day expiry (ATM IV 90.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$70.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a PGEN long call?
The breakeven for the PGEN long call priced on this page is roughly $5.20 at expiration, derived from the November 13, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The PGEN market-implied 1-standard-deviation expected move in the same options snapshot is approximately 25.95%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on PGEN?
Long calls on PGEN express a bullish thesis with defined risk; traders use them ahead of PGEN catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current PGEN implied volatility affect this long call?
PGEN ATM IV is at 90.50% with IV rank near 39.58%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related PGEN analysis